Toronto/Canada | 13 Oct 2023 | Carl Zeiss Meditec AG
VERACITY™ Surgery Planner from ZEISS, a web-based planning software, makes its debut in Canada, helping to create a new era of efficiency and safety for ophthalmic surgical procedures.
Veracity's automated ability to organize relevant diagnostics and patient information has made surgery planning easier for the surgeon and operating room team, and safer for the patient. It truly has been a game-changer for our surgical practice. We could never go back to doing things the old way!
ZEISS VERACITY Surgery Planner creates a seamless digital workflow, using data from electronic medical records and diagnostic devices to help surgeons work faster and make more informed decisions for their patients. VERACITY provides instant, secure access to all relevant patient information and tools in one convenient location so data is available when and where it’s needed.
The introduction of ZEISS VERACITY in Canada will help elevate patient care and surgical precision, setting new standards for healthcare technology in cataract surgery. Moosah Gulam, President at Zeiss Canada, commented, "ZEISS VERACITY is a game-changer in eye care technology. Our mission is to empower medical professionals, streamline workflows, and improve the lives of patients."
Head of Global Communications, ZEISS Ophthalmology
Carl Zeiss Meditec
Phone: +1 925 487 3036
frank.smith@zeiss.com
Brief profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
![Dr. Kashif Baig]({"xsmall":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.100.100.1,0,516,515.file/drbaig.jpg","small":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.360.360.1,0,516,515.file/drbaig.jpg","medium":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.515.515.1,0,516,515.file/drbaig.jpg","large":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.515.515.1,0,516,515.file/drbaig.jpg","xlarge":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.515.515.1,0,516,515.file/drbaig.jpg","xxlarge":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.515.515.1,0,516,515.file/drbaig.jpg","max":"https://www.zeiss.ca/content/dam/med-hcp/canada/press/2023/drbaig.jpg/_jcr_content/renditions/original.image_file.515.515.1,0,516,515.file/drbaig.jpg"} "Dr. Kashif Baig")